clinical trial · NCT05089734
Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Gilead Sciences·phase3·active not recruiting·n = 603
Non-Small Cell Lung CancerSacituzumab Govitecan-hziy (SG)Docetaxel
brief summary
The goal of this clinical study is to compare the study drug, sacituzumab govitecan-hziy (SG), versus docetaxel in participants with advanced or metastatic (cancer that has spread) non-small cell lung cancer (NSCLC).
started
Nov 17, 2021
primary completion
Nov 29, 2023
completion
Jan 1, 2027
last updated
May 7, 2026
official title
Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol